Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

Roche RHHBY announced today that the FDA has approved a label expansion of ophthalmology drug Susvimo (ranibizumab injection). The regulatory body approved the drug Susvimo for the treatment of ...

Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...

Roche said its Susvimo drug received approval from the U.S. drug regulator for the treatment of diabetic retinopathy, a potentially blinding condition. Susvimo can help people with diabetic ...

Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

Approval of Susvimo marks the first continuous delivery therapy indicated for diabetic retinopathy. The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with ...

Roche RHHBY announced today that the FDA has approved a label expansion of ophthalmology drug Susvimo (ranibizumab injection). The regulatory body approved the drug Susvimo for the treatment of ...

22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...